I-131 therapy for thyroid cancer with recombinant human thyroid-stimulating hormone (Thyrogen)
Not Applicable
- Conditions
- Thyroid cancer
- Registration Number
- JPRN-UMIN000005692
- Lead Sponsor
- Kanazawa University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 1
Inclusion Criteria
Not provided
Exclusion Criteria
1) pregnant female and feeding female 2) a patient with disturbed consciousness 3) expected life interval less than 1 month 4) risks for the central nerve system during treatment 5) when medical staff determine that treatment can not be properly carried out
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Assessment of anti-tumor effects with tumor size and tumor markers
- Secondary Outcome Measures
Name Time Method Assessment of harmful effects in bone marrow, digestive organ, and salivary gland